Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Fresenius Submits Application to EMA for Adalimumab Biosimilar

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/18/2017 | 12:02pm CET
   By Sonia Amaral Rohter 
 

Fresenius SE & Co. KGaA (>> Fresenius) said Monday that it has submitted a biosimilar marketing authorization application to the European Medicines Agency for adalimumab.

This is the first biosimilar regulatory filing for Fresenius Kabi, the generic drugs unit, the company said. Fresenius acquired its adalimumab biosimilar this year when it bought Merck KGaA's (>> Merck KGaA) biosimilars business.

Fresenius's drug is a biosimilar candidate of AbbVie Inc.'s (>> AbbVie) Humira, which is used to treat chronic inflammatory autoimmune conditions such as arthritis and Crohn's disease.

Write to Sonia Amaral Rohter at [email protected]

Stocks mentioned in the article : Fresenius, Merck KGaA, AbbVie
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
12:02pDJFresenius Submits Application to EMA for Adalimumab Biosimilar
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
12/13 MERCK : New Partnership to Fight Schistosomiasis in Ethiopia
12/12DJMERCK : Appoints Allan Gabor as Managing Director in China
12/12 MERCK : Allan Gabor Takes Over the Leadership of Merck KGaA, Darmstadt, Germany,..
12/11 REGENEUS LTD (ASX : RGS) Appoints Japan-Based Non-Executive Director with Extens..
12/11 MERCK : EMD Serono - John Walsh, M.D. Joins EMD Serono as Vice President of Neur..
12/11 MERCK : MilliporeSigma Signs Distribution Agreement with Avanti® Polar Lipids
12/10 REGENEUS LTD (ASX : RGS) Appoints Japan-Based Non-Executive Director with Extens..
More news
News from SeekingAlpha
12/14 Perrigo to bid for German Merck's consumer health unit - Reuters
12/04 Merck KGaA's Mavenclad OK'd in Canada
12/01 Suitors preparing bids for Merck KgaA's consumer health unit
11/20 Roche Rocks On With More Good News
11/13 Orexigen Contrave up 10% on Contrave distribution deal with Merck KGaA for La..
Financials (€)
Sales 2017 15 341 M
EBIT 2017 3 325 M
Net income 2017 1 658 M
Debt 2017 9 825 M
Yield 2017 1,40%
P/E ratio 2017 20,48
P/E ratio 2018 20,55
EV / Sales 2017 1,40x
EV / Sales 2018 1,26x
Capitalization 11 700 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 108 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-8.69%13 747
ABBVIE55.62%155 345
KYOWA HAKKO KIRIN CO LTD33.44%11 050
JAZZ PHARMACEUTICALS PLC24.31%8 125
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD34.88%5 638
CONVATEC GROUP-12.01%5 395